Our Experts
-
Laurent Jacquemin
- executive vice president, post-trade derivatives
- SunGard’s capital markets business
- laurent.jacquemin@sungard.com
Laurent Jacquemin is in charge of the post-trade derivatives solutions for SunGard’s capital markets business. In this role, he drives technology and services initiatives aimed at helping agency brokers, Futures Commission Merchants (FCMs) and clearers to reduce their processing costs, manage operational risk and improve client service levels in post-trade listed and cleared OTC derivatives. Prior to joining SunGard, Mr. Jacquemin was managing director for post-trade derivatives at GL Trade. He has more than 18 years of experience in software and systems architecture, product strategy and customer services, 14 of which have been spent in developing technology for capital markets. Mr. Jacquemin is an expert in middle- and back-office applications, brokerage processing, clearance and settlement. He has extensive experience in designing solutions, services architectures and new solution delivery models to enhance straight-through processing (STP) rates.
Commentary
Listed and centrally cleared derivatives transaction volumes have surpassed pre-crisis levels, putting the need to increase STP; reduce processing costs, operational risk and their global TCO; and strengthen risk control processes and tools back on the priority list.
The financial crisis has also introduced a new concept: regulatory risk. Facing this new type of risk, as well as a set of very significant regulatory obligations, market participants are considering major system changes and even adjustments to their business models. Risk management has become even more stringent, time critical and cross-silo.
Regulatory changes within the OTC derivatives, including the Dodd-Frank Act, have increased the volume of complex line items that firms need to integrate and process. At the same time, financial institutions continue to face strong cost pressure in what remains an extremely competitive market for our clients. They require efficient and reliable market connectivity and a unified middle-to back-office processing platform for listed and cleared OTC products.